Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Association of Fitness With Racial Differences in Chronic Kidney Disease.

Paluch AE, Pool LR, Isakova T, Lewis CE, Mehta R, Schreiner PJ, Sidney S, Wolf M, Carnethon MR.

Am J Prev Med. 2019 Jul;57(1):68-76. doi: 10.1016/j.amepre.2019.02.016. Epub 2019 May 21.

PMID:
31122794
2.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
3.

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease.

Dussold C, Gerber C, White S, Wang X, Qi L, Francis C, Capella M, Courbon G, Wang J, Li C, Feng JQ, Isakova T, Wolf M, David V, Martin A.

Bone Res. 2019 Apr 25;7:12. doi: 10.1038/s41413-019-0051-1. eCollection 2019.

4.

Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Bundy JD, Cai X, Scialla JJ, Dobre MA, Chen J, Hsu CY, Leonard MB, Go AS, Rao PS, Lash JP, Townsend RR, Feldman HI, de Boer IH, Block GA, Wolf M, Smith ER, Pasch A, Isakova T; CRIC Study Investigators.

Am J Kidney Dis. 2019 Jun;73(6):806-814. doi: 10.1053/j.ajkd.2019.01.024. Epub 2019 Mar 29.

PMID:
30935773
5.

Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.

Jovanovich A, You Z, Isakova T, Nowak K, Cheung A, Wolf M, Chonchol M, Kendrick J.

Am J Nephrol. 2019;49(4):263-270. doi: 10.1159/000497445. Epub 2019 Feb 28.

PMID:
30820005
6.

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes.

Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, Tuazon J, Safdi A, Scialla J, Susztak K, Isakova T.

Kidney Int Rep. 2018 Sep 18;4(1):94-102. doi: 10.1016/j.ekir.2018.09.006. eCollection 2019 Jan.

7.

Chicago supermarket data and food access analytics in census tract shapefiles for 2007-2014.

Kolak M, Bradley M, Block D, Pool L, Garg G, Toman CK, Boatright K, Lipiszko D, Koschinsky J, Kershaw K, Carnethon M, Isakova T, Wolf M.

Data Brief. 2018 Nov 6;21:2482-2488. doi: 10.1016/j.dib.2018.11.014. eCollection 2018 Dec.

8.

Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD.

Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, Isakova T; CKD Optimal Management with BInders and NicotinamidE (COMBINE) study group.

Kidney Int Rep. 2018 Jul 7;3(6):1467-1472. doi: 10.1016/j.ekir.2018.07.006. eCollection 2018 Nov. No abstract available.

9.

Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.

Akhabue E, Vu TT, Vaidya A, Michos ED, de Boer IH, Kestenbaum B, Allison M, Szklo M, Ouyang P, Yancy CW, Wolf M, Isakova T, Carnethon MR.

Am J Hypertens. 2019 Jan 1;32(1):18-25. doi: 10.1093/ajh/hpy142.

PMID:
30256890
10.

Urban foodscape trends: Disparities in healthy food access in Chicago, 2007-2014.

Kolak M, Bradley M, Block DR, Pool L, Garg G, Toman CK, Boatright K, Lipiszko D, Koschinsky J, Kershaw K, Carnethon M, Isakova T, Wolf M.

Health Place. 2018 Jul;52:231-239. doi: 10.1016/j.healthplace.2018.06.003. Epub 2018 Jul 9.

PMID:
30015180
11.

Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos.

Mehta R, Cai X, Hodakowski A, Thyagarajan B, Zeng D, Zee PC, Wohlgemuth WK, Redline S, Lash JP, Wolf M, Isakova T.

Bone. 2018 Sep;114:278-284. doi: 10.1016/j.bone.2018.06.024. Epub 2018 Jul 3.

PMID:
29986841
12.

Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.

Gerber C, Cai X, Lee J, Craven T, Scialla J, Souma N, Srivastava A, Mehta R, Paluch A, Hodakowski A, Frazier R, Carnethon MR, Wolf MS, Isakova T.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):884-892. doi: 10.2215/CJN.11871017. Epub 2018 May 24.

13.

Microbiome and Cardiovascular Disease in CKD.

Jovanovich A, Isakova T, Stubbs J.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1598-1604. doi: 10.2215/CJN.12691117. Epub 2018 May 9. Review.

PMID:
29743160
14.

FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study.

Akhabue E, Montag S, Reis JP, Pool LR, Mehta R, Yancy CW, Zhao L, Wolf M, Gutierrez OM, Carnethon MR, Isakova T.

Hypertension. 2018 Jul;72(1):70-76. doi: 10.1161/HYPERTENSIONAHA.118.11060. Epub 2018 Apr 30.

PMID:
29712737
15.

Management of stones and bones: reduction of uncertainty through research.

Isakova T, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2018 Jul;27(4):227-228. doi: 10.1097/MNH.0000000000000421. No abstract available.

PMID:
29702492
16.

The phosphate bucket list.

Isakova T, Block G.

Kidney Int. 2018 May;93(5):1033-1035. doi: 10.1016/j.kint.2018.01.010.

PMID:
29680017
17.

A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial.

Wagener EDA, Souma N, Hodakowski A, Martinez C, Fox P, Mehta R, O'Brien MJ, Bolon M, Kulik L, Yang GY, Isakova T; CKD Optimal Management with Binders and NicotinamidE (COMBINE) Investigators.

Kidney Int Rep. 2017 Jul 29;3(1):5-10. doi: 10.1016/j.ekir.2017.07.012. eCollection 2018 Jan. No abstract available.

18.

Longitudinal FGF23 Trajectories and Mortality in Patients with CKD.

Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, Allen NB, Scialla JJ, Pencina MJ, Anderson AH, Talierco J, Chen J, Fischer MJ, Steigerwalt SP, Leonard MB, Hsu CY, de Boer IH, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2018 Feb;29(2):579-590. doi: 10.1681/ASN.2017070772. Epub 2017 Nov 22.

19.

Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.

Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS.

Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/j.ajkd.2017.08.017. Epub 2017 Nov 11.

20.

Continued Search for Therapies to Favorably Modify Phosphate and FGF23 Levels in CKD.

Mehta R, Isakova T.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1911-1913. doi: 10.2215/CJN.11011017. Epub 2017 Oct 26. No abstract available.

21.

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H.

Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.

PMID:
28941764
22.

Validation of highly accelerated real-time cardiac cine MRI with radial k-space sampling and compressed sensing in patients at 1.5T and 3T.

Haji-Valizadeh H, Rahsepar AA, Collins JD, Bassett E, Isakova T, Block T, Adluru G, DiBella EVR, Lee DC, Carr JC, Kim D; CKD Optimal Management with Binders and NicotinamidE (COMBINE) Study Group.

Magn Reson Med. 2018 May;79(5):2745-2751. doi: 10.1002/mrm.26918. Epub 2017 Sep 17.

23.

Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.

Jovanovich A, Isakova T, Block G, Stubbs J, Smits G, Chonchol M, Miyazaki M.

Am J Kidney Dis. 2018 Jan;71(1):27-34. doi: 10.1053/j.ajkd.2017.06.017. Epub 2017 Aug 9.

24.

Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.

Mehta R, Cai X, Hodakowski A, Lee J, Leonard M, Ricardo A, Chen J, Hamm L, Sondheimer J, Dobre M, David V, Yang W, Go A, Kusek JW, Feldman H, Wolf M, Isakova T; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1795-1803. doi: 10.2215/CJN.03950417. Epub 2017 Aug 7.

25.

Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD.

Batacchi Z, Robinson-Cohen C, Hoofnagle AN, Isakova T, Kestenbaum B, Martin KJ, Wolf MS, de Boer IH.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1498-1506. doi: 10.2215/CJN.00530117. Epub 2017 Aug 2.

26.

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. doi: 10.2215/CJN.12821216. Epub 2017 Jul 13.

27.

Acid Load and Phosphorus Homeostasis in CKD.

Khairallah P, Isakova T, Asplin J, Hamm L, Dobre M, Rahman M, Sharma K, Leonard M, Miller E 3rd, Jaar B, Brecklin C, Yang W, Wang X, Feldman H, Wolf M, Scialla JJ; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Am J Kidney Dis. 2017 Oct;70(4):541-550. doi: 10.1053/j.ajkd.2017.04.022. Epub 2017 Jun 21.

28.

Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort.

Ahmad FS, Cai X, Kunkel K, Ricardo AC, Lash JP, Raj DS, He J, Anderson AH, Budoff MJ, Wright Nunes JA, Roy J, Wright JT Jr, Go AS, St John Sutton MG, Kusek JW, Isakova T, Wolf M, Keane MG; CRIC Study Investigators.

Am J Hypertens. 2017 Aug 1;30(8):822-829. doi: 10.1093/ajh/hpx058.

29.

Serum Phosphate and Retinal Microvascular Changes: The Multi-Ethnic Study of Atherosclerosis and the Beaver Dam Eye Study.

Mehta R, Hodakowski A, Cai X, Lee KE, Kestenbaum BR, de Boer IH, Fawzi A, Wong TY, Ix J, Klein B, Klein R, Isakova T.

Ophthalmic Epidemiol. 2017 Dec;24(6):371-380. doi: 10.1080/09286586.2017.1304562. Epub 2017 Apr 12.

30.

Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.

Hsu JY, Roy JA, Xie D, Yang W, Shou H, Anderson AH, Landis JR, Jepson C, Wolf M, Isakova T, Rahman M, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1181-1189. doi: 10.2215/CJN.10301016. Epub 2017 Feb 27.

31.

Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.

Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M; CRIC Study Investigators.

Kidney Int. 2017 Mar;91(3):711-719. doi: 10.1016/j.kint.2016.10.021. Epub 2016 Dec 22.

32.

Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study.

Souma N, Isakova T, Lipiszko D, Sacco RL, Elkind MS, DeRosa JT, Silverberg SJ, Mendez AJ, Dong C, Wright CB, Wolf M.

J Clin Endocrinol Metab. 2016 Oct;101(10):3779-3786. Epub 2016 Aug 8.

33.

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, Chen J, Hamm LL, Ricardo AC, Navaneethan SD, Deo R, Rahman M, Feldman HI, Go AS, Isakova T, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

JAMA Cardiol. 2016 Aug 1;1(5):548-56. doi: 10.1001/jamacardio.2016.1445.

34.

Genetic African Ancestry and Markers of Mineral Metabolism in CKD.

Gutiérrez OM, Parsa A, Isakova T, Scialla JJ, Chen J, Flack JM, Nessel LC, Gupta J, Bellovich KA, Steigerwalt S, Sondheimer JH, Wright JT Jr, Feldman HI, Kusek JW, Lash JP, Wolf M.

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):653-62. doi: 10.2215/CJN.08020715. Epub 2016 Feb 8.

35.

Food Access, Chronic Kidney Disease, and Hypertension in the U.S.

Suarez JJ, Isakova T, Anderson CA, Boulware LE, Wolf M, Scialla JJ.

Am J Prev Med. 2015 Dec;49(6):912-20. doi: 10.1016/j.amepre.2015.07.017.

36.

Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.

Isakova T, Cai X, Lee J, Katz R, Cauley JA, Fried LF, Hoofnagle AN, Satterfield S, Harris TB, Shlipak MG, Sarnak MJ, Ix JH; Health ABC Study.

J Bone Miner Res. 2016 Apr;31(4):742-8. doi: 10.1002/jbmr.2750. Epub 2015 Dec 23.

37.

Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M.

Kidney Int. 2016 Jan;89(1):135-46. doi: 10.1038/ki.2015.290. Epub 2016 Jan 4.

38.

An Introduction to PTH, Phosphate and Vitamin D: Current Issues and Concerns.

Isakova T.

Semin Dial. 2015 Nov-Dec;28(6):563. doi: 10.1111/sdi.12445. Epub 2015 Sep 21. No abstract available.

PMID:
26392014
39.

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.

Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, Schnall AM, Vittinghoff E, Bauer DC, Banerji MA, Cohen RM, Hamilton BP, Isakova T, Sellmeyer DE, Simmons DL, Shibli-Rahhal A, Williamson JD, Margolis KL.

J Clin Endocrinol Metab. 2015 Nov;100(11):4059-66. doi: 10.1210/jc.2015-1215. Epub 2015 Aug 25.

40.

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA.

J Am Soc Nephrol. 2015 Oct;26(10):2328-39. doi: 10.1681/ASN.2015020117. Epub 2015 May 12. Review.

41.

Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial.

Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, Schwartz AV; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.

Bone. 2015 Sep;78:23-7. doi: 10.1016/j.bone.2015.04.037. Epub 2015 Apr 30.

42.

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M; CRIC Study Investigators.

Nephrol Dial Transplant. 2015 Sep;30(9):1534-41. doi: 10.1093/ndt/gfv123. Epub 2015 Apr 24.

43.

Tip-toeing toward the finish line.

Block G, Isakova T.

Nephrol Dial Transplant. 2015 Jan;30(1):1-3. doi: 10.1093/ndt/gfu360. Epub 2014 Nov 20. No abstract available.

44.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

45.

Comparison of mortality of ESRD patients with lupus by initial dialysis modality.

Contreras G, Pagan J, Chokshi R, Virmani S, Diego JM, Byers P, Isakova T, Munoz Mendoza J, Nayer A, Contreras JR, Panama G, Lenz O, Carpintero M, Muchayi T, Roth D.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1949-56. doi: 10.2215/CJN.02500314. Epub 2014 Sep 4.

46.

Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.

Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J.

Rheumatology (Oxford). 2014 Sep;53(9):1613-7. doi: 10.1093/rheumatology/keu151. Epub 2014 Apr 4.

47.

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI.

Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16. Review.

PMID:
24647050
48.

Kidney allograft survival of African American and Caucasian American recipients with lupus.

Contreras G, Li H, Gonzalez-Suarez M, Isakova T, Scialla JJ, Pedraza F, Mattiazzi A, Diaz-Wong R, Sageshima J, Brito Y, Guerra G, Acevedo B, Sajid Ali A, Kershaw TJ, Chen L, Burke GW, Kupin W, Ciancio G, Roth D.

Lupus. 2014 Feb;23(2):151-8. doi: 10.1177/0961203313513819. Epub 2013 Dec 2.

PMID:
24297643
49.

Fibroblast growth factor-23 and cardiovascular events in CKD.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2014 Feb;25(2):349-60. doi: 10.1681/ASN.2013050465. Epub 2013 Oct 24.

50.

Phosphate control in end-stage renal disease: barriers and opportunities.

Waheed AA, Pedraza F, Lenz O, Isakova T.

Nephrol Dial Transplant. 2013 Dec;28(12):2961-8. doi: 10.1093/ndt/gft244. Epub 2013 Jul 30. Review.

Supplemental Content

Loading ...
Support Center